Assessment of mitochondrial electron transport chain function in a primary astrocyte cell model of hyperhomocystinaemia

Toxicology Mechanisms and Methods

Volumn 23, Issue 6, 2013, Pages 459-463

  Turkes, Fiona ^a   Murphy, Elaine ^b   Land, John ^c   Demiray, Berna ^c   Duberley, Kate ^c   Briddon, Antony ^c   Hargreaves, Iain ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b Charles Dent Metabolic Unit   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Homocysteine; Mitochondria; Respiratory chain

Indexed keywords

GLUTATHIONE; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; THIOLACTONE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; HYPERHOMOCYSTEINEMIA; INCUBATION TIME; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; GLUTATHIONE; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MITOCHONDRIA; MODELS, BIOLOGICAL; PRIMARY CELL CULTURE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

RATTUS;

EID: 84879637705     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2013.780276     Document Type: Article

References (41)

1. Baydas G, Reiter RJ, Akbulut M, et al. (2005). Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. Neuroscience 135:879-86.
2. Bell IR, Edman JS, Selhub J, et al. (1992). Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 86:386-90.
3. Chwatko G, Jakubowski H. (2005). Urinary excretion of homocysteinethiolactone in humans. Clin Chem 51:408-15.
4. Clark JB, Nicklas WJ. (1970). The metabolism of rat brain mitochondria. Preparation and characterization. J Biol Chem 245:4724-31.
5. Clarke R, Smith AD, Jobst KA, et al. (1998). Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55:1449-55.
6. Diaz-Arrastia R. (1998). Hyperhomocysteinemia: a new risk factor for Alzheimer disease? Arch Neurol 55:1407-8.
7. Folbergrova J, Jesina P, Drahota Z, et al. (2007). Mitochondrial complex I inhibition in cerebral cortex of immature rats following homocysteic acid-induced seizures. Exp Neurol 204:597-609.
8. Grieve A, Butcher SP, Griffiths R. (1992). Synaptosomal plasma membrane transport of excitatory sulphur amino acid transmitter candidates: kinetic characterisation and analysis of carrier specificity. J Neurosci Res 32:60-8.
9. Gutman I, Wahlefeld WW. (1974). L-lactate determination with lactate dehydrogenase and NAD. In Hu B, ed. Methods of enzymatic analysis. New York: Academic, 1464-8.
10. Halliwell B. (1996). Free radicals, proteins and DNA: oxidative damage versus redox regulation. Biochem Soc Trans 24:1023-7.
11. Harrison J, Hodson AW, Skillen AW, et al. (1988). Blood glucose, lactate, pyruvate, glycerol, 3-hydroxybutyrate and acetoacetate measurements in man using a centrifugal analyser with a fluorimetric attachment. J Clin Chem Clin Biochem 26:141-6.
12. Heales SJ, Lam AA, Duncan AJ, Land JM. (2004). Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 29: 513-19.
13. Ho PI, Ashline D, Dhitavat S, et al. (2003). Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 14:32-42.
14. Isobe C, Murata T, Sato C, Terayama Y. (2005). Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 77:1836-43.
15. Jakubowski H. (1997). Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 272:1935-42.
16. James SJ, Cutler P, Melnyk S, et al. (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80:1611-17.
17. Kim WK, Pae YS. (1996). Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 216:117-20.
18. King TE. (1967). Preparations of succinate - cytochrome c reductase and the cytochrome b-c1 particle, and reconstitution of succinatecytochrome c reductase. Methods Enzymol 10:216-25.
19. Kuhn W, Roebroek R, Blom H, et al. (1998). Hyperhomocysteinaemia in Parkinson's disease. J Neurol 245:811-12.
20. Lindenbaum J, Healton EB, Savage DG, et al. (1988). Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 318:1720-8.
21. Linnebank M, Lutz H, Jarre E, et al. (2006). Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiol Dis 23:725-30.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-75.
23. McCaddon A, Davies G, Hudson P, et al. (1998). Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13:235-9.
24. McCully KS. (1996). Homocysteine and vascular disease. Nat Med 2: 386-9.
25. Moshal KS, Metreveli N, Frank I. (2008). Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 6:84-92.
26. Mudd SH, Levy HL, Kraus JD. (2001). Disorders of transsulfuration. In Scriver CR, Sly WS Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2007-56.
27. Munnich A, Rustin P, Rotig A, et al. (1992). Clinical aspects of mitochondrial disorders. J Inherit Metab Dis 15:448-55.
28. Obeid R, Herrmann W. (2006). Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 580:2994-3005.
29. Plun-Favreau H, Burchell VS, Holmstrom KM, et al. (2012). HtrA2 deficiency causes mitochondrial uncoupling through the Fo-F1 ATP synthase and consequent ATP depletion. Cell Death Dis 3:e335.doi:10.1038/cddis.2012.77.
30. Prins ND, Den Heijer T, Hofman A, et al. (2002). Homocysteine and cognitive function in the elderly: the Rotterdam scan study. Neurology 59:1375-80.
31. Ragan CI, Wilson MY, Darley-Usman VM. (1988). Subfractionation of mitochondria and isolation of proteins of oxidative phophorylation. In Darley VM, Rickwood D Wilson MT, eds. Mitochondria: a practical approach. Oxford: IRL Press, 79-133.
32. Riederer P, Sofic E, Rausch WD, et al. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-20.
33. Riggs KM, Spiro 3rd A, Tucker K, Rush D. (1996). Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 63:306-14.
34. Seshadri S, Beiser A, Selhub J, et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-83.
35. Shepard JA, Garland PB. (1969). Citrate synthase from rat liver. Methods Enzymol 13:11-19.
36. Streck EL, Delwing D, Tagliari B, et al. (2003). Brain energy metabolism is compromised by the metabolites accumulating in homocystinuria. Neurochem Int 43:597-602.
37. Wharton DC, Tzagoloff A. (1967). Cytochrome oxidase from beef heart mitochondria. Methods Enzymol 10:245-50.
38. Yanai Y, Shibasaki T, Kohno N, et al. (1983). Concentrations of sulfurcontaining free amino acids in lumbar cerebrospinal fluid from patients with consciousness disturbances. Acta Neurol Scand 68: 386-93.
39. Ying J, Brennan L. (2008). Effects of homocysteine on metabolic pathways in cultured astrocytes. Neurochem Int 52:1410-15.
40. Zang Y, Marcillat O, Giulivi C, et al. (1990). The oxidative inactivation of mitochondrial electron transport components and ATPase. J Biol Chem 265:16330-6.
41. Zylberstein DE, Lissner L, Bjorkelund C, et al. (2011). Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging 32:380-6.